直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 116921
著者
板東, 浩 Tokushima University|Japan Low Carbohydrate Diet Promotion Association KAKEN研究者をさがす
キーワード
Imeglimin
Twymeeg
Trials of imeglimin for efficacy and safety 2 (TIMES 2)
Glucose-stimulated insulin secretion (GSIS)
Transient receptor potential melastatin 2 (TRPM2) channel
資料タイプ
学術雑誌論文
抄録
Imeglimin (Twymeeg) is novel oral hypoglycemic agent (OHA) developed in the glimin category. It has dual action mechanisms of reducing insulin resistance and increasing insulin secretion. Trials of imeglimin for efficacy and safety 1 (TIMES 1), TIMES 2 and TIMES 3 were performed with significant clinical efficacy. Among them, HbA1c decrease for 52 weeks showed single imeglimin -0.46%, combined therapy of dipeptidyl peptidase-4i (DPP-4i)-0.92%, Glucagon-like peptide-1 receptor agonists (GLP-1RA)-0.12% and insulin -0.63%. From physiological and pharmacological points of view, the mechanism may include the enhancement action of glucose-stimulated insulin secretion (GSIS). For GSIS progress, transient receptor potential melastatin 2 (TRPM2) channel is activated.
掲載誌名
Diabetes Research : Open Journal
ISSN
23796375
出版者
Openventio Publishers
8
1
開始ページ
e1
終了ページ
e3
発行日
2022-03-05
権利情報
This is an open-access article distributed under Creative Commons Attribution 4.0 International License (CC BY 4.0) (https://creativecommons.org/licenses/by/4.0/), which allows to copy, redistribute, remix, transform, and reproduce in any medium or format, even commercially, provided the original work is properly cited.
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系